" class="no-js "lang="en-US"> ABIONYX Pharma - Medtech Alert
Saturday, June 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ABIONYX Pharma | Pharmtech Focus

ABIONYX Pharma

About ABIONYX Pharma

ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.

Related Story

Clinical Trials

 FDA Granted Orphan Drug Designation to CER-001 for the Treatment of LCAT Deficiency | Pharmtech Focus

FDA Granted Orphan Drug Designation to CER-001 for the Treatment of LCAT Deficiency

March 30 2022

ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to […]

Diseases

 ABIONYX Announces New Positive Clinical Results for CER-001 in Kidney Disease Associated with LCAT Deficiency Published in The Journal of Internal Medicine | Pharmtech Focus

ABIONYX Announces New Positive Clinical Results for CER-001 in Kidney Disease Associated with LCAT Deficiency Published in The Journal of Internal Medicine

November 15 2021

ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to […]